The Europe Obesity Intervention Devices Market would witness market growth of 5.1% CAGR during the forecast period (2023-2029).
Patients with diabetes often employ obesity prevention tools because they can lower their chance of developing diabetes-related comorbidities. Patients' risk of getting type 2 diabetes and its complications can be decreased by lowering weight. Additionally, type 2 diabetes in patients with a BMI greater than or equal to 35 has shown improvement or remission due to obesity intervention devices. Therefore, during the forecast period, it is anticipated that the market will grow as diabetes prevalence rises.
The market opportunity will be driven by rising consumer awareness of the harmful impacts of obesity, which is expected to boost demand for these devices. For instance, obesity's negative impacts include a higher chance of heart disease, stroke, particular types of cancer, and other chronic health conditions. Additionally, obesity is linked to a higher risk of mental health problems like anxiety, depression, and others. Additionally, those who are obese are more likely to have joint pain, mobility problems, and other physical limitations.
67% of men and 53% of women in Germany are overweight, which represents a sizeable part of the population. Adult males and adult females who are considered obese average 23% and 24%, respectively. Being overweight and obese can raise the risk of developing chronic diseases and other health issues. Significant healthcare and social welfare costs are a result of the disorders' increased prevalence and linked illnesses. The issue of obesity and being overweight is one that the public takes seriously. Government efforts to combat obesity's rising burden are likely to increase, which will boost demand for obesity intervention tools and support regional market expansion.
The Germany market dominated the Europe Obesity Intervention Devices Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $23.9 million by 2029. The UK market is estimated to grow a CAGR of 4.2% during (2023 - 2029). Additionally, The France market would exhibit a CAGR of 5.9% during (2023 - 2029).
Based on End User, the market is segmented into Hospitals and Clinics & Others. Based on Device, the market is segmented into Gastric Bands, Gastric Balloon and Gastric Stimulation System. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Worldwide Obesity Intervention Devices Market is Projected to reach USD 352 Million by 2029, at a CAGR of 5.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Johnson & Johnson, Apollo Endosurgery, Inc. (Boston Scientific Corporation), ReShape Lifesciences, Inc., AbbVie, Inc., Allurion Technologies, Inc., Spatz FGIA, Inc, Cousin Surgery, A.M.I. GmbH, ENDALIS, and GI Dynamics, Inc.
By End User
By Device
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 